US Fabry sizing runs through two sequential gates, GLA amenability and ADA status, not one, and the second gate is what turns a 5,000-10,000 patient population into a precise 200-400 patient commercial niche.
Diagnosed classic Fabry disease in the US is estimated at 5,000-10,000 patients, roughly 1 in 40,000 males, drawn from NORD and registry sources. That top-line figure understates the true population, since a later-onset, cardiac-predominant phenotype is far more common and largely undiagnosed, but it is the recognised, treatment-relevant base a sizing model has to start from. The first gate inside that population is genetic: an estimated 35-50% of patients carry a GLA mutation amenable to oral migalastat, confirmed by a validated cell-based assay, and that gate alone splits the treated population into an oral-eligible segment and an ERT-only segment with no chaperone option.
The treated population itself splits 60-65% ERT to a growing oral share, and that oral share has moved fast: ERT-naive amenable-mutation patients now start on migalastat 50-60% of the time, reversed from 40-50% choosing ERT as recently as 2020. Inside the ERT-treated population sits the second, sharper gate. An estimated 30-40% of male classic Fabry patients on agalsidase develop high-titre neutralising anti-drug antibodies within three to five years, but only 200-400 US patients currently combine that ADA-positive status with documented inadequate response, the specific, addressable niche that defines Elfabrio's approved label and the only genuinely open commercial opening in a market where agalsidase beta has run unchallenged since 2003. Fabrazyme's WAC of roughly $250,000-350,000 per patient per year is the revenue anchor any sizing model has to apply once that niche is defined.
US Fabry sizing — from diagnosed population to the precise ADA-positive niche
| Sizing Gate | Population Estimate | Source |
|---|---|---|
| Diagnosed classic Fabry (base population) | ~5,000-10,000 patients (~1:40,000 males) | NORD / Fabry registry epidemiology |
| GLA amenable-mutation gate | 35-50% of diagnosed patients | FACETS / ATTRACT amenability data |
| ERT-treated population, ADA-positive | 30-40% develop high-titre ADA within 3-5 years | BALANCE trial ADA sub-analysis |
| Precisely addressable niche (ADA+, inadequate response) | 200-400 patients | BALANCE ADA sub-analysis; Fabry Registry US cohort |
Sources: NORD / Fabry registry epidemiology; Germain DP et al. FACETS, NEJM 2016 (PMID 27509102); Hughes DA et al. ATTRACT, J Med Genet 2017 (PMID 27834756); BALANCE trial ADA sub-analysis, J Med Genet 2024 (PMID 37940383); Fabry Registry US patient cohort; Amicus investor day 2024.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Amenable-mutation fraction and the cell-based assay gate
- the 60-65% ERT versus growing oral-share treated-population split
- the 2020-to-present oral-preference reversal among ERT-naive amenable patients
Delivers
- The 30-40% high-titre ADA development rate on agalsidase
- the documented-inadequate-response criteria that narrow the cohort to 200-400 patients
- sensitivity ranking of this gate against the broader amenability split
Delivers
- The $250,000-350,000 WAC anchor and its application to the 200-400 patient niche
- revenue scenarios at conservative, base, and aggressive capture assumptions
- sensitivity of total addressable revenue to ADA-testing infrastructure
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why the ADA-positive gate, not the amenable-mutation gate, is the assumption that decides the sharpest addressable number
- Pressure-tested against the Elfabrio label criteria before the rest of the model is built out
- Diagnosed classic Fabry prevalence (~5,000-10,000; ~1:40,000 males)
- The undiagnosed later-onset cardiac-predominant pool excluded from this base
- The 35-50% GLA-amenable-mutation split
- The 30-40% ADA-development rate and the 200-400 patient inadequate-response cohort
- Cross-check against Fabry Registry US cohort data and Amicus investor-day uptake figures
- Confidence range around the 200-400 patient point estimate
- ADA-testing infrastructure ranked against amenable-mutation rate as the binding assumption
- Scenario ranges tied to ADA ELISA testing expansion at major US Fabry centres
- The full triangulated model, re-runnable with your own assumptions
- The open sizing questions your team must close before the number is used in planning
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx market sizing model triangulates at least two independent methods, epidemiology-based and clinical-trial or registry-based, before accepting a patient count. This is explicitly a sizing model (static patient count), distinct from a Patient Flow or forecasting model.
US Fabry sizing sources: NORD and Fabry registry epidemiology, FACETS (NEJM 2016), ATTRACT (J Med Genet 2017), the BALANCE trial ADA sub-analysis (J Med Genet 2024), the Fabry Registry US patient cohort, and Amicus investor day 2024 uptake data.
- Diagnosed classic Fabry prevalence verified against NORD and Fabry registry epidemiology sources
- Amenable-mutation fraction verified against FACETS, NEJM 2016 (PMID 27509102) and ATTRACT, J Med Genet 2017 (PMID 27834756)
- ADA-positive addressable niche sizing verified against BALANCE trial ADA sub-analysis, J Med Genet 2024 (PMID 37940383) and Fabry Registry US cohort data
Frequently asked questions
Commission this model
AXLRx delivers rare disease market sizing models built for forecasting and strategy teams sizing the US Fabry opportunity. Custom model in 72 hours.
Specify your indication, market, and cohort definition.
AXLRx analyst confirms triangulation methods and comparator set before building.
Research-verified sizing model in 72 hours with optional analyst readout.